Carlsmed, Inc. (CARL)vsDoximity Inc (DOCS)
CARL
Carlsmed, Inc.
$15.77
+3.00%
HEALTHCARE · Cap: $372.95M
DOCS
Doximity Inc
$33.63
-1.81%
HEALTHCARE · Cap: $6.10B
Smart Verdict
WallStSmart Research — data-driven comparison
Doximity Inc generates 936% more annual revenue ($655.57M vs $63.30M). DOCS leads profitability with a 25.5% profit margin vs -57.4%. DOCS earns a higher WallStSmart Score of 57/100 (C).
CARL
Avoid30
out of 100
Grade: F
DOCS
Buy57
out of 100
Grade: C
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Intrinsic value data unavailable for CARL.
Margin of Safety
+49.3%
Fair Value
$51.22
Current Price
$33.63
$17.59 discount
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Revenue surging 56.7% year-over-year
Conservative balance sheet, low leverage
Conservative balance sheet, low leverage
Safe zone — low bankruptcy risk
Every $100 of equity generates 21 in profit
Keeps 26 of every $100 in revenue as profit
Growing faster than its price suggests
Strong operational efficiency at 21.5%
Areas to Watch
0.0% earnings growth
Distress zone — elevated risk
Smaller company, higher risk/reward
ROE of -43.1% — below average capital efficiency
Weak financial health signals
Premium valuation, high expectations priced in
Earnings declined 51.9%
Comparative Analysis Report
WallStSmart ResearchBull Case : CARL
The strongest argument for CARL centers on Revenue Growth, Debt/Equity. Revenue growth of 56.7% demonstrates continued momentum.
Bull Case : DOCS
The strongest argument for DOCS centers on Debt/Equity, Altman Z-Score, Return on Equity. Profitability is solid with margins at 25.5% and operating margin at 21.5%. PEG of 0.59 suggests the stock is reasonably priced for its growth.
Bear Case : CARL
The primary concerns for CARL are EPS Growth, Altman Z-Score, Market Cap.
Bear Case : DOCS
The primary concerns for DOCS are Piotroski F-Score, P/E Ratio, EPS Growth. A P/E of 40.3x leaves little room for execution misses.
Key Dynamics to Monitor
CARL profiles as a hypergrowth stock while DOCS is a mature play — different risk/reward profiles.
CARL is growing revenue faster at 56.7% — sustainability is the question.
DOCS generates stronger free cash flow (42M), providing more financial flexibility.
Monitor HEALTH INFORMATION SERVICES industry trends, competitive dynamics, and regulatory changes.
Bottom Line
DOCS scores higher overall (57/100 vs 30/100), backed by strong 25.5% margins. Both earn "Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Carlsmed, Inc.
HEALTHCARE · HEALTH INFORMATION SERVICES · USA
Carlsmed, Inc. develops and operates a surgical platform for the treatment of complex adult spinal deformities that enables surgeons to harness clinical intelligence, advanced image recognition, and 3D printing technologies. The company is headquartered in Carlsbad, California.
Doximity Inc
HEALTHCARE · HEALTH INFORMATION SERVICES · USA
Doximity, Inc. (Ticker: DOCS) is a U.S. healthcare technology company that operates a digital platform tailored for medical professionals. The company’s cloud-based network provides secure communication and collaboration tools, telemedicine services, clinical workflow solutions, and access to medical news, research, and career-management features for physicians, nurse practitioners, physician assistants, and other clinicians. Headquartered in San Francisco, California, Doximity’s Class A common stock trades on the New York Stock Exchange under the ticker DOCS.
Compare with Other HEALTH INFORMATION SERVICES Stocks
Want to dig deeper into these stocks?